• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Authors


Ashley Son, MS

Latest:

Contributor: Patient-Centered Approaches to Supporting Medication Adherence Among Persons With Schizophrenia

There are effective strategies that can be employed concurrently to promote adherence to medications for schizophrenia, including but not limited to pharmacological, technological, and psychosocial interventions.


Quinn Everts

Latest:

How Understanding Risk Factors Can Help Patients With Chronic Diseases Quit Smoking

How much does education about the specific risks of smoking assist in smoking cessation?


R. Scott Leslie, PhD, MPH

Latest:

Scenario Analysis When Conducting Budget Impact Analyses for Rare Diseases

The authors propose conducting a scenario analysis for interventions to treat rare diseases by varying health plan size to demonstrate the variability of potential budget impact.


Ann Marie Huffenberger, DBA, RN, NEA-BC

Latest:

Economics of a Health System’s Direct-to-Consumer Telemedicine for Its Employees

A direct-to-consumer telemedicine service resulted in lower per-episode unit costs for care within 7 days and only marginally increased the use of services overall.


Jeffrey Crowley, MPH

Latest:

Future of PrEP

Experts in HIV provide closing thoughts on the future of PrEP, including improvement of uptake and addressing access disparities.


Randi Foraker, PhD, MA

Latest:

Using Electronic Health Records and Claims Data to Identify High-risk Patients Likely to Benefit From Palliative Care

Deep learning algorithms could improve palliative care by predicting mortality from electronic health records and claims data.


Alan Gabot, PharmD

Latest:

Cost-Benefit Analysis of Sacubitril/Valsartan in a Medicaid Population

The cost avoidance of heart failure–related hospitalizations and emergency department visits may outweigh the additional drug cost in Medicaid members adherent to sacubitril/valsartan.


Emel Sezer, MD

Latest:

Evaluation of Biosimilar Trastuzumab MYL-1401O in HER2-Positive Breast Cancer

The authors evaluate the effect and safety of biosimilar trastuzumab MYL-1401O in human epidermal growth factor receptor 2 (HER2)–positive early-stage (neoadjuvant and adjuvant therapy) and metastatic (palliative therapy) breast cancer using real-world data.


Jessi Humphreys, MD

Latest:

Reimagining the Inpatient Palliative Care Consult: Lessons From COVID-19

Digital innovations in palliative care during COVID-19 have changed how hospitalized patients receive palliative care. We propose an approach to implement new models at scale.


Mattijs E. Numans, PhD

Latest:

Identifying Complex Patients Using Adjusted Clinical Groups Risk Stratification Tool

In this study, the authors developed a method for use in primary care to identify a group of patients with complex care needs using Aggregated Diagnosis Groups.


Shelley A. Jazowski, PhD, MPH

Latest:

Association Between Low-Income Subsidies and Inequities in Orally Administered Antimyeloma Therapy Use

Medicare Part D low-income subsidies alone are insufficient to improve the uptake and equitable use of high-cost, orally administered antimyeloma therapy.


Kristina M. Cordasco, MD, MPH, MSHS

Latest:

Patients’ Needs Following Emergency Care for Ambulatory Care–Sensitive Conditions

To inform intervention development, we assessed for medication changes and patient care needs following treat-and-release Veterans Affairs emergency department visits for chronic ambulatory care–sensitive conditions.


Kristi Rosa

Latest:

FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation

Revumenib has been approved for relapsed or refractory acute leukemia with KMT2A translocation in patients aged 1 year and older.



Mary Reyes, MD

Latest:

Service Line Care Delivery Model for COVID-19 Patient-Centric Care

The authors provide steps hospitals can take to align their care delivery model to effectively meet the demands of a public health crisis such as the current pandemic.



Chad Cannon, PharmD, BCCCP

Latest:

Private Label Biosimilars

The expert panel discusses the greater potential for private label biosimilars.



Salama Freed, PhD

Latest:

Risk Adjusting for Medicaid Participation in Medicare Advantage

When comparing risk-adjustment approaches based on Medicaid status of Medicare beneficiaries, this analysis found that predicted spending levels varied depending on states’ Medicaid eligibility criteria.


Leah Lovgren, MS

Latest:

Long-Term Health Care Costs Following COVID-19: Implications for Pandemic Preparedness

A difference-in-differences analysis of health care claims data evaluated excess health care costs in the 12 months following COVID-19 diagnosis among the general and older adult populations.


Samuel Moy, BS

Latest:

Variation in Spending Associated With Primary Care Practices

Physician practices account for a significant amount of variation in spending.


Lauretta Dozier, RN

Latest:

Leveraging Longitudinal Clinical Laboratory Results to Improve Prenatal Care

Collaboration between a clinical laboratory and a managed care organization improved prenatal care and outcomes through real-time, actionable, laboratory-derived insights and care coordination.


Laura C. Chambers, PhD, MPH

Latest:

Long-Term Health Care Costs Following COVID-19: Implications for Pandemic Preparedness

A difference-in-differences analysis of health care claims data evaluated excess health care costs in the 12 months following COVID-19 diagnosis among the general and older adult populations.


Martin Dawes, MBBS, MD, FRCGP, CCFP

Latest:

Contributor: The Case for Education and Clinical Decision Support With Pharmacogenetics

Prescribing is a complex process with multiple factors to consider on top of the 3 primary questions about effectiveness, harm, and cost. Pharmacogenetics has put this complexity under the spotlight and prompted educational programs and the development of new clinical decision support systems.


Francesca L. Beaudoin, MD, PhD, MS

Latest:

Long-Term Health Care Costs Following COVID-19: Implications for Pandemic Preparedness

A difference-in-differences analysis of health care claims data evaluated excess health care costs in the 12 months following COVID-19 diagnosis among the general and older adult populations.


Leonce Nshuti, MSc

Latest:

Trends in Medicare Part D Coverage of Generics With Equivalent Brand-Name Drugs

High-tier generic drug placement in Medicare Part D has increased over time, but it may be related to a drug’s clinical profile and availability of substitutes rather than preferred brand-name drug coverage.


Alexander Wu, MSc

Latest:

Cost Analysis of Self-Monitoring Blood Glucose in Nonintensively Managed Type 2 Diabetes

Analysis of claims data showed reduced utilization and costs among patients with nonintensively managed type 2 diabetes using self-monitoring of blood glucose compared with continuous glucose monitoring.


Cameron Santoro
Cameron Santoro

Latest:

FDA Approves Zanidatamab-hrii for HER2+ Biliary Tract Cancer

Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.


Felippe Ottoni Marcondes, MD, MPH

Latest:

The Effect of Medicare Eligibility on Diagnosis of Chronic Conditions

Medicare coverage did not necessarily lead to increased diagnosis of chronic conditions.


© 2024 MJH Life Sciences
AJMC®
All rights reserved.